You are invited

YUPELRI® revefenacin inhalation solution

The Role of Nebulized Long-Acting Maintenance Treatment of COPD in the Long-Term Care Setting

Featured Speaker	Gregory Smith, APRN, FNP-BC/PMHNP-BC Nurse Practitioner Curana Health Care
Date	Tuesday, November 10, 2026 6:00 PM ET
Location	Mckendrick's Steak House 4505 Ashford Dunwoody Road Atlanta, GA 30346
RSVP	Stacy Cape (864) 417-5012 Stacy.Cape@viatris.com

The purpose of the meeting will be to educate healthcare professionals on the role of YUPELRI in the treatment of patients with chronic obstructive pulmonary disease. This program is not eligible for continuing medical education.

Indication

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta$_2$-agonist.

See additional Important Safety Information on reverse side.

Important Safety Information (cont)

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

Please see accompanying Full Prescribing Information.

This program is intended for US healthcare professionals of appropriate specialties **only**. Please contact your Viatris™ representative should you have any questions as to who is permitted to attend the attached program.

Viatris will report any transfers of value and/or in-kind benefits in accordance with Federal and/or State requirements. Minnesota, Vermont, and Federal Entities (eg, VA, DoD) have restrictions on receiving certain transfers of value and/or in-kind benefits, including meals and refreshments, at industry-sponsored events. Please refer to the program host regarding any questions or concerns.

Viatris may not pay for or provide alcohol at speaker programs.

YUPELRI and the Yupelri Logo are registered trademarks of Viatris Specialty LLC. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

© 2025 Viatris Inc. All Rights Reserved.
REV-2020-0435 V5

YUPELRI® revefenacin inhalation solution